These findings have important implications for the development of novel therapeutic strategies for the treatment of septic cardiomyopathy, highlighting the potential of targeting the FGF2–FUNDC1 axis as a promising approach for mitigating cardiac dysfunction in sepsis. Here, FGF2 is linked to Sepsis.